Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals

Chemokines influence HIV neuropathogenesis by affecting the HIV life cycle, trafficking of macrophages into the nervous system, glial activation, and neuronal signaling and repair processes; however, knowledge of their relationship to in vivo measures of cerebral injury is limited. The primary objective of this study was to determine the relationship between a panel of chemokines in cerebrospinal fluid (CSF) and cerebral metabolites measured by proton magnetic resonance spectroscopy (MRS) in a cohort of HIV-infected individuals. One hundred seventy-one stored CSF specimens were assayed from HIV-infected individuals who were enrolled in two ACTG studies that evaluated the relationship between neuropsychological performance and cerebral metabolites. Concentrations of six chemokines (fractalkine, IL-8, IP-10, MCP-1, MIP-1β, and SDF-1) were measured and compared with cerebral metabolites individually and as composite neuronal, basal ganglia, and inflammatory patterns. IP-10 and MCP-1 were the chemokines most strongly associated with individual cerebral metabolites. Specifically, (1) higher IP-10 levels correlated with lower N-acetyl aspartate (NAA)/creatine (Cr) ratios in the frontal white matter and higher MI/Cr ratios in all three brain regions considered and (2) higher MCP-1 levels correlated with lower NAA/Cr ratios in frontal white matter and the parietal cortex. IP-10, MCP-1, and IL-8 had the strongest associations with patterns of cerebral metabolites. In particular, higher levels of IP-10 correlated with lower neuronal pattern scores and higher basal ganglia and inflammatory pattern scores, the same pattern which has been associated with HIV-associated neurocognitive disorders (HAND). Subgroup analysis indicated that the effects of IP-10 and IL-8 were influenced by effective antiretroviral therapy and that memantine treatment may mitigate the neuronal effects of IP-10. This study supports the role of chemokines in HAND and the validity of MRS as an assessment tool. In particular, the findings identify relationships between the immune response—particularly an interferon-inducible chemokine, IP-10—and cerebral metabolites and suggest that antiretroviral therapy and memantine modify the impact of the immune response on neurons

Disrupted cerebral metabolite levels and lower nadir CD4+ counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatmentpatients on stable treatment

AbstractCognitive impairment and brain injury are common in people with HIV/AIDS, even when viral replication is effectively suppressed with combined antiretroviral therapies (cART). Metabolic and structural abnormalities may promote cognitive decline, but we know little about how these measures relate in people on stable cART. Here we used tensor-based morphometry (TBM) to reveal the 3D profile of regional brain volume variations in 210 HIV+ patients scanned with whole-brain MRI at 1.5T (mean age: 48.6±8.4years; all receiving cART). We identified brain regions where the degree of atrophy was related to HIV clinical measures and cerebral metabolite levels assessed with magnetic resonance spectroscopy (MRS). Regional brain volume reduction was linked to lower nadir CD4+ count, with a 1–2% white matter volume reduction for each 25-point reduction in nadir CD4+. Even so, brain volume measured by TBM showed no detectable association with current CD4+ count, AIDS Dementia Complex (ADC) stage, HIV RNA load in plasma or cerebrospinal fluid (CSF), duration of HIV infection, antiretroviral CNS penetration-effectiveness (CPE) scores, or years on cART, after controlling for demographic factors, and for multiple comparisons. Elevated glutamate and glutamine (Glx) and lower N-acetylaspartate (NAA) in the frontal white matter, basal ganglia, and mid frontal cortex — were associated with lower white matter, putamen and thalamus volumes, and ventricular and CSF space expansion. Reductions in brain volumes in the setting of chronic and stable disease are strongly linked to a history of immunosuppression, suggesting that delays in initiating cART may result in imminent and irreversible brain damage

Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV

In the present study, we examined the relationships among cognitive function, magnetic resonance spectroscopy (MRS) brain metabolite indices measured in the basal ganglia, and quantitative magnetic resonance imaging (MRI) of the caudate nucleus and the putamen in the earliest stages of HIV-related cognitive involvement. Participants included 22 HIV-positive individuals and 20 HIV-negative individuals. HIV-positive individuals performed significantly more poorly than the HIV-negative individuals on several cognitive measures. In addition, the choline/creatine ratio was significantly higher and the N-acetyl aspartate/choline ratio was significantly lower among HIV patients. The caudate and putamen sizes were smaller among HIV-positive patients compared with controls; however, the differences did not reach statistical significance. Correlation analyses revealed associations between cognitive function and select MRS indices. In addition, caudate size was significantly correlated with performances on higher-order thinking tests whereas putamen size was significantly correlated with performances on motor tests. The results suggest that MRS differences are more pronounced than area size differences between seropositive and seronegative individuals in mild stages of HIV-related cognitive impairment. However, basal ganglia size remains an important contributor to cognitive status in this population. Longitudinal studies are needed to determine the evolution of these imaging correlates of HIV-cognitive impairment in HIV

Human immunodeficiency virus type 1 infection associated dementia

La demencia asociada a infección por virus de inmunodeficiencia humana (DVIH) es una entidad caracterizada por la tríada de compromiso cognitivo, síntomas conductuales y motores, que generan serias dificultades en la capacidad funcional del paciente. Las múltiples denominaciones generan confusión y alta probabilidad de subreconocimiento. No obstante, la incidencia de DVIH es controversial; se tiene claro que más de 90% de pacientes con sida tiene anormalidades neuropatólogicas compatibles con DVIH. Los mecanismos patogénicos involucran una compleja interacción entre el VIH y las células del cerebro, que generan claramente dos vías incluyentes, la inflamatoria y la no inflamatoria, las cuales generan factores neurotóxicos y quimiotácticos, inductores de apoptosis, que conducen a una disrupción neuronal-glial, probablemente responsable de la injuria y/o muerte neuronal, que conduciría a un fenómeno de neurodegeneración acelerada. Los síntomas son de una demencia subcortical, siendo los síntomas de presentación más comunes el compromiso de la memoria, enlentecimiento mental, dificultad para la marcha y depresión. El diagnóstico es esencialmente clínico y se realiza por exclusión. Son de utilidad práctica la HIV Dementia Scale (HDS) y la International HIV Dementia Scale (IHDS), como pruebas iniciales de descarte. El tratamiento debe incluir la combinación de antiretrovirales y neuroprotectores. Como conclusión, la DVIH es una complicación devastadora de la infección por VIH que debe ser reconocida tempranamente.Dementia associated to human immunodeficiency virus infection (DHIV) is an entity distinguished by three main signs -cognitive, behavioral and motor symptoms- which generate serious difficulties in the functional capacity of the patient. The multiple denominations generate confusion and diagnostic difficulties. In spite of controversy in DHIV incidence, it is clear that more than 90% of patients with AIDS has compatible neuropathological anormalities with DHIV. The pathogenic mechanisms involve complex interactions between the HIV and the brain cells generating two inclusive paths, inflammatory and non inflammatory, that produce neurotoxic and chemotactic factors, inductors of apoptosis that lead to neuro-glial disruption probably responsible of injury and/or neuron cell death, that finally would lead to accelerated neurodegeneration phenomenon. Symptoms are subcortical dementia, mental sluggishness, walking difficulties and depression. Diagnosis is essentially clinical and by exclusion. The HIV Dementia Scale (HDS) and the International HIVD Scale (IHDS) are of practical usefulness as initial screening tests. Treatment should include the combination of antiretrovirals and neuroprotectors. We conclude that DHIV is a devastating complication of HIV infection that should have early recognition

1H-MRS neurometabolite profiles and motor development in school-aged children who are HIV-exposed uninfected: a birth cohort study

ObjectiveAlterations in regional neurometabolite levels as well as impaired neurodevelopmental outcomes have previously been observed in children who are HIV-exposed uninfected (CHEU). However, little is known about how neurometabolite profiles may relate to their developmental impairment. This study aimed to compare neurometabolite concentrations in school-aged CHEU and children who are HIV-unexposed (CHU) and to explore associations of neurometabolite profiles with functional neurodevelopment in the context of perinatal HIV exposure.MethodsWe used 3 T single voxel proton magnetic resonance spectroscopy (1H-MRS) to quantify absolute and relative neurometabolites in the parietal gray and parietal white matter in school-aged CHEU and aged- and community-matched CHU. Functional neurodevelopmental outcomes were assessed using the early learning outcome measure (ELOM) tool at 6 years of age.ResultsOur study included 152 school-aged children (50% males), 110 CHEU and 42 CHU, with an average age of 74 months at the neuroimaging visit. In an adjusted multiple linear regression analysis, significantly lower glutamate (Glu) concentrations were found in CHEU as compared to CHU in the parietal gray matter (absolute Glu, p = 0.046; Glu/total creatine (Cr+PCr) ratios, p = 0.035) and lower total choline to creatine ratios (GPC+PCh/Cr+PCr) in the parietal white matter (p = 0.039). Using factor analysis and adjusted logistic regression analysis, a parietal gray matter Glu and myo-inositol (Ins) dominated factor was associated with HIV exposure status in both unadjusted (OR 0.55, 95% CI 0.17–0.45, p = 0.013) and adjusted analyses (OR 0.59, 95% CI 0.35–0.94, p = 0.031). With Ins as one of the dominating metabolites, this neurometabolic factor was similar to that found at the age of two years. Furthermore, this factor was also found to be correlated with ELOM scores of gross motor development in CHEU (Pearson’s r = −0.48, p = 0.044). In addition, in CHEU, there was a significant association between Ins/Cr+PCr ratios in the parietal white matter and ELOM scores of fine motor coordination and visual motor integration in CHEU (Pearson’s r = 0.51, p = 0.032).ConclusionReduced Glu concentrations in the parietal gray matter may suggest regional alterations in excitatory glutamatergic transmission pathways in the context of perinatal HIV and/or antiretroviral therapy (ART) exposure, while reduced Cho ratios in the parietal white matter suggest regional myelin loss. Identified associations between neurometabolite profiles and gross and fine motor developmental outcomes in CHEU are suggestive of a neurometabolic mechanism that may underlie impaired motor neurodevelopmental outcomes observed in CHEU

Biological And Clinical Markers Of Neuronal Injury In Primary And Chronic Hiv-1 Infection

The use of antiretroviral therapy (ART) has shifted the neurological manifestations of HIV-1 infection toward mild but debilitating HIV-associated neurocognitive disorder (HAND). Through two studies, we sought to characterize neuronal injury during primary and chronic HIV infection and to describe its relationship with HAND. The aim of the first study was to quantify cerebrospinal fluid (CSF) and neuroimaging biomarkers of neuronal injury in primary HIV infection (PHI). We compared CSF levels of neurofilament light chain (NFL), tau, and amyloid proteins in 92 subjects with PHI and 25 controls and examined relationships with disease progression and neuroinflammation, neuropsychological testing, and proton-magnetic resonance spectroscopy (MRS). We hypothesized that PHI is characterized by increased CSF NFL that correlates with neuronal inflammation, and that tau and amyloid levels are normal in PHI. NFL was elevated in PHI (p=0.0004) and correlated with CSF neopterin (r=0.38, p=0.0005), IP-10 (r=0.39, p=0.002), WBCs (r=0.32, p=0.004), and CSF:plasma albumin ratio (r=0.60, p\u3c0.0001). NFL correlated with decreased N-acteylaspartate and glutamate in the anterior cingulate, frontal white matter, and parietal gray matter (r\u3e0.30, p\u3c0.05). Beta-amyloid was elevated in PHI (p=0.0005) and correlated with time infected (r=0.34, p=0.003). Neither marker correlated with neuropsychological abnormalities. T-tau and amyloid precursor proteins did not differ between groups. The aim of the second study was to characterize HIV-infected patients with neuro-symptomatic CSF `escape,\u27 defined as detectable CSF HIV RNA in the setting of treatment-suppressed plasma levels or CSF RNA \u3e1 log higher than plasma RNA. We conducted a retrospective case series of virologically controlled HIV-infected patients on ART with progressive neurological abnormalities who were determined to have CSF `escape\u27 at 4 urban medical centers in the United States and Europe. We recorded levels of CSF HIV RNA and inflammatory markers, clinical signs and symptoms, and magnetic resonance imaging (MRI) findings. We hypothesized that individuals with this condition would have inflammation in CSF and MRI studies, that CSF virus would be resistant to the ART regimen, and that symptoms would improve when ART was changed based upon central nervous system (CNS) drug penetration and resistance genotyping. 10 patients presented with sensory, motor, and cognitive abnormalities. Median CSF HIV RNA was 3900 copies/mL; median plasma HIV RNA was 62 copies/mL. Median CD4+ T cell count was 482 cells/mm3. All patients had been controlled \u3c500 copies/mL for median 27.5 months and 5/10 had been suppressed \u3c50 copies/mL for median 19.5 months. Patients were on a stable ART regimen for median 21 months. All had CSF pleocytosis or elevated CSF protein; 7/8 had MRI abnormalities; and 6/7 harbored CSF resistance mutations. Following optimization of ART, 8/9 patients improved clinically. Although these processes occur at distinct time points in the disease, both neuronal injury during PHI and the development of symptomatic CSF `escape\u27 in chronic, well-treated infection are associated with, and possibly caused by, mechanisms involving immune activation and inflammation within the CNS. The inflammatory milieu induced by the activity of HIV in invading cells and triggering an immune response has important implications throughout the time course of infection, and may be particularly important for understanding the pathophysiology of HAND

Development of Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) Methods to Study Pathophysiology Underlying Neurodegenerative Diseases in Murine Models

Manganese-enhanced magnetic resonance imaging (MEMRI) opens the great opportunity to study complex paradigms of central nervous system (CNS) in freely behaving animals and reveals new pathophysiological information that might be otherwise difficult to gain. Due to advantageous chemical and biological properties of manganese (Mn2+), MEMRI has been successfully applied in the studies of several neurological diseases using translational animal models to assess comprehensive information about neuronal activity, morphology, neuronal tracts, and rate of axonal transport. Although previous studies highlight the potential of MEMRI for brain imaging, the limitations concerning the use of Mn2+ in living animals and applications of MEMRI in neuroscience research are in their infancy. Therefore, development of MEMRI methods for experimental studies remains essential for diagnostic findings, development of therapeutic as well as pharmacological intervention strategies. Our lab has been dedicating to develop novel MEMRI methods to study the pathophysiology underlying neurodegenerative diseases in murine models. In the first study, we investigated the cellular mechanism of MEMRI signal change during neuroinflammation in mice. The roles of neural cells (glia and neurons) in MEMRI signal enhancement were delineated, and ability of MEMRI to detect glial (astrocyte and microglia) and neuronal activation was demonstrated in mice treated with inflammatory inducing agents. In vitro work demonstrated that cytokine-induced glial activation facilitates neuronal uptake of Mn2+,and that glial Mn2+ content was not associated with glial activation. The in vivo work confirmed that MEMRI signal enhancement in the CNS is induced by astrocytic activation by stimulating neuronal Mn2+ uptake. In conclusion, our results supported the notion that MEMRI reflects neuronal excitotoxicity and impairment that can occur through a range of insults that include neuroinflammation. In the second study, we evaluated the efficacy of MEMRI in diagnosing the complexities of neuropathology in an ananimal model of a neurodegenerative disease, neuroAIDS. This study demonstrated that MEMRI reflects brain region specific HIV-1-induced neuropathology in virus-infected NOD/scid-IL-2Rγcnull humanized mice. Altered MEMRI signal intensity was observed in affected brain regions. These included, but were not limited to, the hippocampus, amygdala, thalamus, globus pallidus, caudoputamen, substantia nigra and cerebellum. MEMRI signal was coordinated with levels of HIV-1 infection, neuroinflammation (astro- and micro- gliosis), and neuronal injury. Following the application of MEMRI to assess HIV-1 induced neuropathology in immune deficient mice humanized with lymphoid progenitor cells, our successful collaboration with Dr. Sajja BR (Department of Radiology, UNMC, Omaha, NE) led to the generation of a MEMRI-based NOD/scid-IL-2Rγcnull (NSG) mouse brain atlas. Mouse brain MRI atlases allow longitudinal quantitative analyses of neuroanatomical volumes and imaging metrics. As NSG mice allow human cell transplantation to study human disease, these animals are used to assess brain morphology. MEMRI provided sufficient contrast permitting 41 brain structures to be manually labeled on average brain of 19 mice using alignment algorithm. The developed atlas is now made available to researchers through Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) website (https://www.nitrc.org/projects/memribrainatlas/). Finally, we evaluated the efficacy of N-acetylated-para-aminosalicylic acid (AcPAS) to accelerate Mn2+ elimination from rodent brain, enabling repeated use of MEMRI to follow the CNS longitudinally in weeks or months as well as inhibiting the confounding effects of residual Mn2+ from preceding administrations on imaging results. Two-week treatment with AcPAS (200 mg/kg/dose × 3 daily) accelerated the decline of Mn2+ induced enhancement in MRI. This study demonstrated that AcPAS could enhance MEMRI utility in evaluating brain biology in small animals

Comparison of Magnetic Resonance Spectroscopy (MRS) data in children with and without HIV at 11-12 years

Although HIV and antiretroviral drugs have been shown to cause damage in the brain, the long-term impacts of perinatal infection, early treatment and exposure in children at 11 years, remain unclear. The effects of HIV and antiretroviral therapy (ART), whilst indistinguishable, can be investigated at a chemical level through proton magnetic resonance spectroscopy (1H-MRS). Previous studies in children have largely focused on individual metabolite changes. However, several adult studies have now advanced beyond this to address patterns of metabolic activity that are altered with HIV infection. Using a 3T Skyra scanner, 136 children (76 HIV+, 30 HEU, 30 HU; 71 males) between the ages of 11.0- 12.5 years, and from a similar socioeconomic background, were scanned. In this study metabolite concentrations were quantified within the basal ganglia (BG), midfrontal gray matter (MFGM) and peritrigonal white matter (PWM). We utilised linear regression to investigate individual metabolite differences, comparing HIV-infected (HIV+) children from the Children with HIV Early Antiretroviral Therapy (CHER) trial, and HIV-exposed-uninfected (HEU) children, to HIV-unexposed (HU) children. Pearson's correlation analysis, factor analysis and logistic regression were then used to study alterations in metabolic patterns between HIV+ and HIV-uninfected (HIV-) children. Analysis of the data was carried out in R. We found elevated total choline in the BG (p = 0.03) and MFGM (p < 0.001) of HIV+ children, as well as reduced PWM total NAA (p = 0.03) and total creatine (p = 0.01). Altered metabolite concentrations were further observed in HEU children. Additionally, we identified a cross-regional coupling of choline which distinguishes HIV+ from HIV- children (p < 0.001). These findings indicate that multiregional inflammation and PWM axonal damage are occurring in HIV+ children at 11 years. Ultimately, the consequences of perinatal HIV acquisition, in spite of early treatment, continue to be seen at 11 years, as do the impacts of exposure

Multivoxel magnetic resonance spectroscopy of the brain in HIV+ patients

UVOD: Neurokognitivni poremećaj udružen sa HIVinfekcijom (HIV associated neurocognitive disorder- HAND) javlja se u oko polovine pacijenata sa HIV-om. HAND obuhvata spektar neuroloških poremećaja koji variraju od asimptomatskog neurokognitivnog poremećaja(ANI), preko blagog kognitivnog oštećenja, koje se naziva blagi kognitivni poremećaj (MND) do demencije udružene sa HIV-om (HAD). U evaluaciji i dijagnostici ovog poremećaja koriste se razne laboratorijske, kliničke i metode imidžinga, među kojima magnetno-rezonantni imidžing (MRI) zauzima posebno mesto u pogledu dijagnostike strukturnih poremećaja. Međutim, za dijagnostiku suptilnih supcelularnih neurobiohemijskih poremećaja neophodno je korišćenje magnetno-rezonantne spektroskopije (MRS). Klasično shvatanje promena u neurobiohemijskom profilu kod pacijenata sa HIV infekcijom uključuje: sniženje NAA (neuronskog markera) kao odraz neurodegeneracije, povišenje Cho (markera razgradnje membrana) kao odraz inflamacije/ apoptoze, povišenje mI (markera proliferacije mikroglije) kao odraz inflamacije i povišenje Glx+Gln (markera glutaminergične ravnoteže) kao odraz ekscitotoksičnosti. Do sada u literaturi nije opisano korišćenje multivokselske MRS mozga na HIV+ pacijentima. CILJEVI: Ciljevi studije su bili: utvrditi da li postoje promene u odnosima koncentracija metabolita u mozgu dobijenih metodom multivokselske MRS u neurološki asimptomatskih HIV+ pacijenata u poređenju sa zdravim kontrolnim ispitanicima,zatim da li postoje razlike između pacijenata na kombinovanoj antiretroviralnoj terapiji (cART) i pacijenata bez cART; utvrditi da li postoji i kakva je povezanost odnosa metabolita dobijenih MRS sa imunološkim parametrima HIV+ pacijenata i nivoom nadir CD4+ T-limfocita; i konačno, utvrditi da li postoji i kakva je povezanost dobijenih odnosa metabolita sa parametrima penetracije antiretroviralne terapije u centralni nervni sistem. ISPITANICI I METODE: U studiju je uključeno ukupno 114 ispitanika (32 HIV+ pacijenta na cART, prosečne starosti 41.97 godina (25-61); 28 HIV+ pacijenata bez cART, prosečne starosti 35.21 godina (24-52); 50 kontrolnih, zdravih subjekata prosečne starosti 36.56.godina (19-53)). Svi ispitanici su potpisali informisani pristanak za učešće u studiji. Ispitivanje je odobreno od strane Etičke komisije Instituta za onkologiju Vojvodine, kao i Etičke komisije Medicinskog fakulteta Univerziteta u Novom Sadu. Kriterijum za uključenje pacijenata u studiju je bio prisustvo HIV infekcije. Kriterijumi za isključivanje pacijenata iz studije su bili: prisustvo aktivne oportunističke infekcije, prisustvo aktivnog neurološkog oboljenja, podatak o aktivnoj zloupotrebi narkotika, koinfekcija virusom hepatitisa B i C, prisustvo lezija bele ili sive mase i kontraindikacije za snimanje na aparatu za magnetnu rezonancu. 4 ispitanika su isključena iz ispitivanja. Svim ispitanicima urađeni su skrining neurokognitivni testovi, kao i rutinska laboratorijska ispitivanja (broj CD4+, CD3+ i CD8+ limfocita). Nakon toga, svim ispitanicima urađen je konvencionalni MRI praćen multivokselskom MRS supratentorijalne suprakalozalne bele mase. Ispitivano je ukupno 12 voksela (6 u sivoj i 6 u beloj masi), odnosno preko 7900 spektara. Određeni su pikovi karakterističnih metabolita. Na metodi dugog eha analizirana su tri glavna pika: NAA na 2.0ppm, Cho na 3.2ppm i tCr na 3.ppm, izražena preko odnosa koncentracija NAA/Cr i Cho/Cr. Na metodi kratkog eha analizirani su signali NAA, Cho, Cr te mI na 3.5ppm i Glx+Gln na 2.2-2.4ppm. Ovi signali su izraženi kroz odnose koncentracija NAA/Cr, Cho/Cr, mI/Cr i (Glx+Gln)/Cr. Za statističku obradu podataka korišćen je IBM SPSS ver. 21.0. Deskriptivna statistika je uključila određivanje srednje vrednosti, minimuma, maksimuma i standardne devijacije. Razlike između posmatranih grupa ispitanika za sve kontinuirane varijable ispitivane su jednofaktorskom analizom varijanse (ANOVA) sa naknadnim (post-hoc) testovima za koje je korišćena metoda po Tukey-ju. Rezultati su prikazani u vidu srednjih vrednosti, standardne devijacije, najviše i najniže izmerene vrednosti (maksimum i minimum), i za svaki ispitivani parametar pridružena je vrednost F i p. Veza između kontinuiranih varijabli je ispitivana pomoću koeficijenta Pirsonove linearne korelacije, uz prethodnu proveru zadovoljavanja uslova o homogenosti varijansi, normalnosti raspodele i linearnosti. Vrednosti p<0.05 su uzimane kao statistički značajne. REZULTATI: Pokazano je da su HIV+ pacijenti na cART značajno stariji od druge dve grupe ispitanika. Nije pokazana značajna razlika u stepenu obrazovanja među grupama. Pokazano je da godine života statistički značajno utiču samo na koncentracije NAA/Cr, dok na odnose drugih metabolita ne utiču značajno. Utvrđeno je statistički značajno sniženje (p<0.05) koncentracija NAA/Cr dobijenih metodom dugog eha između tri grupe ispitanika na svim posmatranim vokselima. Naknadnim analizama utvrđena je statistički značajna razlika na 10/12 voksela između HIV+ pacijenata sa cART i zdravih, kao i između HIV+ pacijenata bez terapije i zdravih, dok su se koncentracije NAA/Cr značajno razlikovale između HIV+ pacijenata sa i bez cART samo na jednom vokselu (duboka frontalna bela masa levo). Utvrđena je statistički značajna razlika u smislu sniženja Cho/Cr odnosa dobijenih metodom dugog eha u 5/12 voksela, sa pojedinačnim vokselima koji su prikazivali razlike između grupa. Na metodi kratkog eha utvrđeno je značajno sniženje odnosa koncentracija NAA/Cr kod HIV+ pacijenata samo na tri voksela, pri čemu nisu prikazane značajne razlike između dve grupe pacijenata sa HIV infekcijom (sa i bez cART). Rezultati odnosa koncentracija Cho/Cr između tri gurpe pacijenata dobijeni metodom kratkog eha slični su rezultatima dobijenim na metodi dugog eha (statistički značajna razlika dobijena je na 5/12 voksela). Što se tiče odnosa koncentracija mI/Cr, uočeno je značajno povišenje ovog odnosa kod HIV+ pacijenata u odnosu na zdrave na 6/12 voksela. Prikazano je statistički značajno povišenje ovog markera kod pacijenata bez cART u odnosu na pacijente sa cART samo u regiji levog dorzalnog anteriornog cinguluma. Statistički značajno povišenje (Glx+Gln)/Cr odnosa je prikazano u regiji zadnjeg cinguluma desno kod pacijenata na terapiji u odnosu na pacijente bez terapije, dok na drugim vokselima nije prikazana značajna razlika. Vokseli 4, 7 i 10 su dali najviše informacija(supkortikalna bela masa frontalno levo, dorzalni prednji cingulum levo te parijetalni supkorteks leve cerebralne hemisfere), sa prikazanim značajnim razlikama u bar 4 odnosa metabolita. Prikazana je značajna pozitivna korelacija nadir CD4 + broja limfocita sa koncentracijama NAA/Cr, a negativna sa odnosima Cho/Cr i mI/Cr, što čini nadir CD4+ najboljim serološkim prediktorom neurodegenerativnog oštećenja. Pokazana je pozitivna korelacija indeksa penetracije lekova u monocite (ME) sa odnosima NAA/Cr i negativna korelacija indeksa penetracije lekova u centralni nervni sistem (CPE) sa Cho/Cr i mI/Cr. Došli smo do zakljulka da je ME indeks bolji marker neurodegenerativnog odgovora a CPE indeks bolji u monitoringu kontrole inflamacije. ZAKLJUČAK: Smatra se da HIV virus uzrokuje prerano starenje mozgašto je prvenstveno posledica direktnog oštećenja nervnih ćelija samim virusom (preko viralnih proteina, indukovanih citokina i hemokina). Pokazali smo da su neuronski gubitak i neurodegeneracija proces koji zahvata celokupan volumen mozga, dok su procesi inflamacije i proliferacije mikroglije svedeni na tačno određene regione, pretežno sive mase. Visoka senzitivnost multivokselske 1H-MRS sa korišćenjem senzitivnih površinskih kalemova omogućava mapiranje metabolita sa prostornom rezolucijom. MRS može dati ključni uvid u promene koncentracija metabolita mozga tokom razvoja infekcije od akutne i primarne do hronične. Vrlo brzo nakon serokonverzije, dolazi do detektabilnih promena u metabolitima mozga u smislu neuronskog oštećenja i inflamacije. U našem istraživanju su po prvi put analizirani rezultati protonske multivokselske MRS bele i sive mase velikog mozga u suprakalozalnom regionu. Utvrđeno je da postoje difuzne, ali ipak visoko regionalno-zavisne promene u odnosima neurometabolita kod pacijenata koji dobijaju antiretroviralnu terapiju i kod pacijenata koji je ne dobijaju, u poređenju sa zdravim kontrolnim ispitanicima (odgovarajućim po polu i starosti). Dodatne studije sa posmatranjem apsolutnih koncentracija neurometabolita, kao i longitudinalne studije u koje su uključeni HIV+ pacijenti u različitim fazama bolesti, su neophodne za dalje i bolje razumevanje neuropatogeneze HAND-a. MRS se pokazala uspešnom u detekciji efikasnosti određenih terapijskih opcija. Dva postojeća indeksa za procenu efikasnosti antiretroviralne terapije (CPE, ME) odvojeno pogađaju dva puta neuropatogeneze kognitivnog poremećaja, sa različitim uspehom u sveobuhvatnoj proceni efekta i efikasnosti terapije. U budućnosti je potrebna njihova pojedinačna modulacija ili kreiranje jedinstvenog indeksa, koji bi obuhvatio i efikasnost prolaza leka kroz hematoencefalnu barijeru i dejstvo na latentni rezervoar HIV-a u ćelijama monocitno-makrofagne loze.INTRODUCTION: HIV associated neurocognitive disorder- HAND appears in about half of the HIV+ patients. HAND represents a spectrum of neurological disorders varying from asymptomatic neurocognitive impairment (ANI), over mild neurocognitive disorder (MND) to HIV associated dementia (HAD). For evaluation and diagnostics of this disorder, many laboratory, clinical and imaging methods are used, first of all magnetic resonance imaging (MRI). Nevertheless, for detecting subtle subcellullar neurobiochemical disorders, the use of magnetic resonance spectroscopy (MRS) is necessary. Classical pattern of neurobiochemical changes in HIV infection consist of: decrease in NAA (neuronal marker) depicting neurodegeneration, increase in Cho (metabolism on membrane marker) depicting inflammation/ apoptosis, increase in mI (marker of microglial proliferation) depicting inflammation and increase in Glx+Gln (glutaminergic balance marker) depicting the effect of excytotoxicity. To the best of our knowledge, this is the first study using multivoxel MRS of the brain in HIV+ patients. AIMS: The aims of this study were: to show whether there are differences in metabolites' ratios on multivoxel MRS in neurologically asymptomatic HIV+ patients compared to control subjects; whether there are differences in metabolites' ratios between patients on combined antiretroviral therapy (cART) and therapy-naive ones; whether there are correlations between matebolites' ratios and immunological parameters in HIV+ patients as well as with nadir CD4+ count; whether there are correlations between metabolites' ratios with parameters of drugs' penetration in central nervous system (CNS). SUBJECTS AND METHODS: Overall of 114 subjects were enrolled in the study (32 HIV+ paients on cART, average age 41.97 years (25-61); 28 HIV+ patients off cART, average age 35.21 years (24-52); 50 control subjects, average age 36.56 years (19-53)). All the subjects signed the informed consent. The study was ethically approved by Ethical committee of Vojvodina Oncology Institute and Ethical committee of Faculty of Medicine, University of Novi Sad. Inclusion criteria for HIV+ subjects were: the presence of HIV infection. Exclusion criteria included: active opportunistic infection, active neurological illness, usage of drugs of abuse, hepatitis B or C coinfection, presence of both white or grey matter lesions, and contraindications that apply for magnetic resonance (MR) examination. 4 subjects were excluded from the study due to the presence of white matter lesions (3 HIV+ and one control subject). Each patient performed International HIV Dementia Scale (IHDS), a screening test for evaluation of global cognitive status in HIV-infected patients. Baseline study laboratory variables were assessed (CD4+ T-lymphocyte count and plasma HIV RNA, nadir CD4+ counts and CD4+ T-cell counts at the moment of MR scan. Conventional MRI scan was followed by multivoxel MRS with both long and short echo. We analyzed 12 voxels (6 in grey and 6 in white matter) with overall of over 7900 spectra. Finally, we analyzed following dominant signals: on the long echo tCr (creatine plus phosphocreatine) at 3.0 ppm, NAA (N-acetyl-aspartate) at 2.0 ppm and Cho (choline containing compounds) at 3.2ppm (ratios of NAA/Cr and Cho/Cr were assessed); on the short echo tCr, NAA, Cho, (Glx+Gln) at 2.2-2.4ppm and mI (myoinositol) at 3.5ppm (ratios of NAA/Cr, Cho/Cr, (Glx+Gln)/Cr and mI/Cr were assessed. All statistical calculations were performed using IBM SPSS software (version 21.0, Chicago, IL, USA). Descriptive statistics included determination of mean values, minimum, maximum and standard deviation. Among-group differences (HIV infected subjects versus healthy controls) in acquired metabolite ratios were evaluated using ANOVA with post hoc Tukey test to determine the differences between separate groups. Due to a known impact of age and education on the NAA concentrations, differences in NAA/Cr ratios among groups were tested using ANCOVA, with age as a covariate variable. Testing relationships between continuous variables was performed using Pearson linear correlation. Statistical significance was set at value p<0.05. RESULTS: We showed that HIV+ patients on therapy were significantly older than the other two groups of patients. There was no significant difference in the level of education. We confirmed that the age significantly affects the level of NAA/Cr only.There was significant decrease (p<0.05) in NAA/Cr level on long echo MRS among three groups on all the observed voxels. Post hoc analysis showed that there was significant difference in 10/12 voxels between HIV+ patients on cART and healthy controls and between HIV+ patients off cART and controls, while NAA/Cr differed significantly between HIV+ patients on and off cART in only one voxel (deep frontal white matter on the left). There was decrease in Cho/Cr levels on long echo MRS in 5/12 voxels among three groups. On short echo MRS, we showed decrease in NAA/Cr level in 3/12 voxels, while there were no differences between two groups of HIV+ patients. Results of short echo MRS in the means of Cho/Cr resembled long echo MRS. There was significant increase in mI/Cr level in HIV+ patients in 6/12 voxels compared to healthy controls, while there was difference in only one voxel between HIV+ patients on and off therapy (dorsal part of anterior cingulate on the left). Significant increase in (Glx+Gln)/Cr level was present between HIV+ patients on and off therapy in the region of right posterior cingulate. Voxels 4, 7 and 10 were the most informative ones (subcortical frontal white matter on the left, dorsal part of left anterior cingulate and right posterior cingulate), showing significant differences in 4 metabolites' ratios. We showed positive correlation between nadir CD4+ count and NAA/Cr and negative correlation between nadir CD4+ count and Cho/Cr, and nadir CD4+ count and mI/Cr, which made nadir CD4+ count the best serological predictor of neurodegeneration. Positive correlation was showed between monocyte efficacy (ME) index and NAA/Cr, while negative correlation was present between CNS penetration efficacy (CPE), Cho/Cr and mI/Cr. We concluded that ME better depicted neurodegenerative process while CPE was better in monitoring of inflammation. CONCLUSIONS: HIV causes premature ageing of the brain, in the means of cognition, attention, working memory and executive function. These effects are due to direct affection of neurons by virus per se (viral proteins, induced cytokines and chemokynes). We showed tha neuronal loss and neurodegeneration affect the whole volume of the brain while inflammation and glial proliferation affect restricted areas predominantly in grey matter. High sensitivity of multivoxel MRS with use of sensitive surface coils enables metabolite mapping with high spatial resolution. MRS can give essential data on metabolites' changes during the evolution of the infection from acute, over primary to chronic. Early after seroconversion, metabolites' changes can be detected (neuronal dysfunction and inflammation).To the best of our knowledge, this is the first study using multivoxel MRS of the brain in HIV infection in human population, analyzing data from supracallosal grey and white matter. We showed the presence of diffuse but regionally highly specific changes in metabolites' ratios in patients on cART and off cART, compared to age and gender matched healthy controls. Additional studies with absolute concentrations of metabolites, as well as longitudinal studies with HIV+ patients in different stages of the disease, are necessary for better understanding of neuropathogenesis of HAND. We showed that MRS can be useful tool in evaluation of therapy regimens efficacy. Two available indices for evaluation of cART efficacy target two separate pathways of cognitive disorder pathogenesis, with different reliability in evaluation of effect and efficacy of applied therapy. In the future, their modulation or creation of new index is needed, in order to include drug delivery through the blood-brain barrier as well as the effect on latent reservoir of HIV in monocyte/macrophage cells

Formulation and evaluation of an implantable polymeric configuration for application in AIDS Dementia Complex

Drug delivery to the brain has challenged medical professionals for several decades, with 98% of small molecules and 100% of large molecules unable to cross the blood brain barrier (BBB). Biocompatible, biodegradable polymers have been extensively researched for the oral delivery of therapeutic agents, but to date has not been successfully manipulated for the formulation of an implantable device. We have therefore utilised such polymers for the formulation and design of an implantable nanoenabled multipolymeric drug delivery device (NMDDD) for the management of AIDS Dementia Complex (ADC). ADC is a central nervous system (CNS) complication of HIV, associated with a host of debilitating cognitive, motor and behavioural symptoms. ADC remains a serious manifestation of HIV/AIDS in both developing and developed countries, affecting both adults and children, with death expected within 6 months of initial diagnosis. Zidovudine (AZT), the current gold standard for the management of ADC, has demonstrated the best penetration into the CNS. It is capable of reducing viral replication in the CNS and managing neurological abnormalities associated with ADC, with clinical efficacy evidenced by the decline in morbidity and mortality of patients treated with this drug. Nanotechnology, an interdisciplinary field of research, involving the manipulation of matter on a submicron level, is receiving emerging interest for the formulation of novel drug delivery systems. As they can potentially be manipulated to react in a bioresponsive manner, nanopharmaceuticals have received much attention for site-specific drug delivery and were therefore employed in the formulation of an implantable NMDDD, with AZT employed as the model drug, for the management of ADC. Nanoparticles were prepared by means of an approach utilising controlled gelation of alginate, employing cationic crosslinking of the anionic alginate to precipitate nanoparticles. A 3-factor Box-Behnken statistical design was employed for the optimisation of nanoparticle and multipolymeric scaffold formulations. Nanoparticles measuring 68.04nm (SD<0.0002) in size with a zeta potential of -13.4mV (SD<0.0005) were formulated. Nanoparticles presented with a mean dissolution time (MDT) of 46.046 hours 30 days post exposure to phosphate buffered saline (PBS), pH 7.4. In an attempt to further retard drug release and to formulate a device for implantation in the frontal lobe of the brain, nanoparticles were dispersed within a robust multipolymeric matrix. Matrix erosion was calculated at 28%w/w (SD<0.001) for multipolymeric scaffold and a matrix resilience of 4.451%w/w (SD<0.007) was observed 30 days post exposure to PBS, indicating slow degradation of the NMDDD. MDT was reduced to 12.570 hours (SD<0.0005) with dispersion of the nanoparticles within a polymer matrix, supporting the application of the drug-loaded MDDD in the management of ADC patients. The optimised multipolymeric nanoparticulate scaffold was implanted into the frontal lobe of the rat brain, for investigation of drug release characteristics and tissue response to the device following in vivo administration